[Form 4] Haemonetics Corporation Insider Trading Activity

Rhea-AI Filing Summary

Amaze Holdings, Inc. (NYSE American: AMZE) filed an Item 3.02 Form 8-K reporting a private placement completed between 7 July and 23 July 2025.

• Securities sold: 444,040 common shares
• Cash received: US $2,601,011 (≈ $5.86 per share)
• Commitment shares: 2,468 additional shares issued to the investor
• Purchaser: C/M Capital Master Fund, LP
• Documentation: Transaction governed by the Securities Purchase Agreement dated 6 May 2025, previously disclosed on 7 May 2025
• Registration status: Shares issued under the Section 4(a)(2)/Rule 506(b) private-offering exemption; not registered with the SEC

The filing provides no updated financials or guidance. Proceeds strengthen liquidity, but the issuance adds to share count and may dilute existing holders. No other material events were disclosed.

Positive

• $2.6 million in gross proceeds strengthens near-term liquidity without incurring underwriting fees
• Use of Reg D/Section 4(a)(2) exemption expedites funding and avoids market-pricing uncertainty associated with public offerings

Negative

• Issuance of 446,508 new shares (including commitment shares) introduces dilution to existing shareholders
• Concentration of shares with a single fund may create future resale overhang and influence corporate actions

Insights

Capital Markets Analyst

TL;DR $2.6 m cash boost via exempt offering; modest dilution, neutral-to-slightly positive for liquidity.

The private sale injects immediate capital without underwriting costs, a plus for a micro-cap issuer that likely faces high public-offering friction. At ≈$5.86 per share, pricing appears near-market (exact market price not provided), limiting discount risk. However, 446,508 new shares (including commitment shares) enlarge the float; without outstanding-share data, potential dilution can’t be quantified, but for small-cap structures this could be meaningful. Because the buyer is a single fund, future resale overhang remains a consideration. Overall impact leans neutral: liquidity improves, offset by dilution and resale risk.

Corporate Governance Expert

TL;DR Single-investor placement concentrates influence; governance vigilance advised.

A single institutional purchaser now holds a new block, possibly gaining negotiation leverage in future financings or corporate actions. The commitment-share feature effectively lowers the purchaser’s entry cost, underscoring asymmetry versus public shareholders. Board transparency appears adequate—prior agreement was already disclosed—but investors should monitor any related-party provisions and resale registration rights that could pressure the share price. No shareholder approval was required under Nevada law or NYSE American rules due to issuance size, so procedural risk is limited.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Johnson Lloyd Emerson

(Last) (First) (Middle)

125 SUMMER STREET

(Street)

BOSTON MA 02110

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
HAEMONETICS CORP [ HAE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
07/24/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/24/2025		A		2,693(1)	A	(2)	12,933	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.

2. Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

	/s/ Thomas V. Powers, attorney-in-fact for Mr. Johnson	07/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many shares did Amaze Holdings (AMZE) issue in July 2025?

The company issued 444,040 common shares for cash and 2,468 commitment shares, totaling 446,508 new shares.

What amount of capital did Amaze Holdings raise through the private placement?

Amaze Holdings received US $2,601,011 in gross proceeds.

Who purchased the shares from Amaze Holdings?

All shares were sold to C/M Capital Master Fund, LP under a previously disclosed purchase agreement.

Were the new Amaze Holdings shares registered with the SEC?

No. The shares were issued under Section 4(a)(2) and Rule 506(b) exemptions and are unregistered.

Will current shareholders experience dilution from this transaction?

Yes. The additional 446,508 shares increase the outstanding share count, diluting existing holdings.